GlassScriptPhysician profile
Benjamin David Shivar
NPI 1992195184
$9,817.99
in general payments reported to CMS, 2019-2025
34 companies · $3,167 in 2025
The $3,167 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $924 · 2022: $953 · 2023: $2,204 · 2024: $2,570 · 2025: $3,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,940.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,867.25 | 2021-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $955.13 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Jazz Pharmaceuticals INC. | $726.63 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $617.71 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Glaxosmithkline, LLC. | $597.02 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $581.78 | 2021-2025 | Dupixent |
| Insmed, INC. | $539.66 | 2021-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $490.91 | 2022-2025 | |
| Mylan Specialty L.P. | $462.18 | 2021-2024 | Yupelri |
| Harmony Biosciences LLC | $384.41 | 2022-2025 | Wakix |
| Electromed, INC. | $337.94 | 2021-2025 | Smartvest |
| Viatris Specialty LLC | $272.92 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $262.45 | 2024-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $256.16 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Mallinckrodt Hospital Products INC. | $246.34 | 2022-2025 | Acthar |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $194.46 | 2021-2024 | Keytruda, Belsomra, Recarbrio |
| Verona Pharma, INC. | $181.68 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $159.19 | 2024-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $120.28 | 2021-2025 | Tyvaso, Tyvaso |
| Intuitive Surgical, INC. | $117.97 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $65.93 | 2025 | Lumryz |
| Lilly USA, LLC | $62.18 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $60.20 | 2021-2022 | |
| Amgen INC. | $37.97 | 2025 | Tezspire |
| Shionogi INC | $31.60 | 2023-2024 | Fetroja |
| Inogen, INC. | $28.79 | 2022-2025 | |
| Vifor Pharma, INC. | $25.93 | 2025 | Zemaira |
| Alexion Pharmaceuticals, INC. | $21.73 | 2022 | |
| Inspire Medical Systems, INC. | $20.93 | 2023 | Inspire |
| Baxter Healthcare | $20.11 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Axsome Therapeutics, INC. | $19.99 | 2024 | Sunosi |
| Resmed Corp | $18.67 | 2022 | |
| Melinta Therapeutics, LLC | $18.15 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Shivar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.